Loading
institutionsInstitution
Comprehensive Cancer Center Mainfranken, University Hospital Würzburg
The university where Röntgen discovered X-rays, now a world centre for CAR-T and bispecific antibodies in multiple myeloma under Hermann Einsele.
Also called: CCC MainfrankenUniversitätsklinikum WürzburgNCT WERA
Overview
Wilhelm Conrad Röntgen discovered X-rays at Würzburg in 1895, the founding moment of radiation medicine. Today the CCC Mainfranken is a German Cancer Aid Oncology Center of Excellence and, with Erlangen, Regensburg and Augsburg, one of the National Center for Tumor Diseases sites (NCT WERA) since 2023. Hermann Einsele's Department of Internal Medicine II has been a leading European site for BCMA-directed CAR-T and bispecific antibodies in myeloma, including the CARTITUDE and MajesTEC programmes, and was among the first in Europe to treat patients with these agents. The centre also has strong programmes in stem cell transplantation, neuro-oncology, nuclear medicine and theranostics, and translational immunology.
Location
Würzburg, DE
Type
cancer center · Julius-Maximilians-Universität Würzburg
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#138 · 34 points (0 Newsweek + 0 NCI + 34 from 17 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Universitätsklinikum Würzburg, including child institutions. 817 works · 12,349 citations · 73% open access · 12% clinical trials · 1% reviews.
Oncology works per year
1792022
1882023
1802024
1572025
1132026
Most works
- Michael Hudecek93 works
- Hermann Einsele84 works
- Leo Rasche48 works
- Bastian Schilling43 works
- Max S. Topp43 works
- Johannes Duell38 works
- Anja Gesierich31 works
- Andreas Konrad Buck31 works
- Dirk Schadendorf31 works
- Alexander Hann31 works
Most cited
- Multiple myeloma CAR-T and bispecifics
- Stem cell transplantation
- Theranostics
- NCT WERA
Similar pages
- Key paperCARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma
Shares Legend Biotech, Ciltacabtagene autoleucel, ICANS (neurotoxicity), BCMA.
- TrialLEGEND-2
Shares Legend Biotech, Ciltacabtagene autoleucel, BCMA, Johnson & Johnson.
- TrialA Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind
Shares Teclistamab, Ciltacabtagene autoleucel, Johnson & Johnson, T-cell engagers (bispecific).
- TrialA Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Shares Ciltacabtagene autoleucel, Johnson & Johnson, T-cell engagers (bispecific), CAR-T cell therapy.
- Key paperCARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy
Shares Legend Biotech, Ciltacabtagene autoleucel, BCMA, Cytokine release syndrome (CRS).
- Key paperMagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response
Shares GPRC5D, Teclistamab, BCMA, Cytokine release syndrome (CRS).
- InstitutionIRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola
Shares Teclistamab, BCMA, Bispecific antibodies, CAR-T cell therapy.
- PairingBCMA-directed therapy → GPRC5D-directed therapy
Shares GPRC5D, Teclistamab, BCMA, Multiple myeloma.
cancers
fronts
technologies
targets
drugs
ApprovedCAR-T (BCMA)
Ciltacabtagene autoleucel · Carvykti
ApprovedBispecific T-cell engager (BCMA×CD3)
Teclistamab · Tecvayli